Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, with business highlights issued July 30, 2026.
AGIOS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, with business highlights issued July 30, 2026
- Detailed financial results and operating updates contained in Exhibit 99.1 press release
- Information furnished under Item 2.02, limiting its treatment as filed information under Section 18 of the Exchange Act
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 mitapivat revenue $44.7M, up from $12.5M, indicating accelerating commercial adoption
- AQVESME launch generated 442 cumulative U.S. thalassemia prescriptions by June 30, 2026
- Mitapivat sickle-cell sNDA received FDA Priority Review, with November 1, 2026 PDUFA goal date
- Cevidoplenib licensing added ITP pipeline potential of up to $1.0B in peak U.S. sales, with $25.0M upfront payment
- Cash, equivalents and marketable securities declined to $964.8M from $1.2B, while Q2 net loss remained $100.7M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AGIOS PHARMACEUTICALS, INC. 8-K filings
Get the next AGIO 8-K as it lands
Follow AGIO for push alerts, or ask the research agent what this filing means.